RevvityLTS:0KHE -1.39%75 FCF Margin % is 13.42% as of Mar. 2026, which is 18% below its 10-year median of 16.46. GuruFocus rates LTS:0KHE with a GF Score™ of 75/100 and a GF Value™ of $119.87 (Fairly Valued). The stock has 11 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Revvity ranks better than 84.73% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Revvity's Free Cash Flow for the
three
months ended in Mar. 2026 was $95 Mil. Revvity's Revenue for the
three
months ended in Mar. 2026 was $711 Mil. Therefore, Revvity's FCF Margin % for the quarter that ended in Mar. 2026 was 13.42%.
The historical rank and industry rank for Revvity's FCF Margin % or its related term are showing as below:
LTS:0KHE'
s FCF Margin % Range Over the Past 10 Years
Min: 0.36 Med: 16.46 Max: 34.61
Current: 16.98
During the past 13 years, the highest FCF Margin % of Revvity was 34.61%. The lowest was 0.36%. And the median was 16.46%.
LTS:0KHE's FCF Margin % is ranked better than 84.73% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.89
vs LTS:0KHE: 16.98
Revvity FCF Margin % Related Terms
Revvity FCF Margin % Historical Data
* Premium members only.
The historical data trend for Revvity's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KHE vs ICLR, CRL, MEDP: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Revvity's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revvity FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Revvity's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revvity (LTS:0KHE) has a FCF Margin % of 13.42% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Revvity and its competitors. This is 18% below median its historical median of 16.46. Over the past decade, Revvity's FCF Margin % has ranged from 0.36 to 34.61. According to the industry distribution chart, Revvity ranks #31 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 15.3%.
Is Revvity's FCF Margin % too high?
Revvity's current FCF Margin % of 13.42% is 18% below median its 10-year median of 16.46. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 34.61. Based on the distribution chart, Revvity ranks #31 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Revvity has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Revvity's FCF Margin % compare to ICLR and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Revvity ranks #31 out of 203 companies for FCF Margin %. This places Revvity in the top 15% of its industry — outperforming the majority of peers. Historically, Revvity's own FCF Margin % has ranged from 0.36 to 34.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Revvity and its competitors. Revvity's current FCF Margin % is 13.42%, which is 18% below median its own 10-year median of 16.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revvity stock overvalued right now?
Based on GuruFocus' analysis, Revvity (LTS:0KHE) is currently considered Fairly Valued. The stock's GF Value™ is $119.87, compared to a current price of $112.44 — trading 6.2% below its estimated fair value. The current FCF Margin % is 13.42%, which is 18% below median its 10-year median of 16.46. Revvity's overall GF Score™ is 75/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Revvity (LTS:0KHE), the current FCF Margin % is 13.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revvity (LTS:0KHE) Overvalued in 2026?
Based on GuruFocus' analysis, Revvity stock appears to be undervalued.
The current stock price of $112.44 is trading 6.2% below its estimated GF Value™ of $119.87.
GuruFocus considers Revvity to be Fairly Valued.
Key valuation signals for LTS:0KHE:
FCF Margin %: 13.42% (18% below median its 10-year median of 16.46)
GF Value™: $119.87 vs. price of $112.44 (6.2% below fair value)
No single metric tells the full story. See the LTS:0KHE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
75GF Score
Get the complete analysis for LTS:0KHE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KHE has been successfully added to your 
